The fibrin-derived peptide Bβ15–42 has been shown to reduce infarct size in rodent models of ischemia-reperfusion injury. To increase its potential for translation into the clinic, we studied the effects of Bβ15–42 in pigs, whose coronary anatomy is similar to that of humans. In addition, we evaluated the pharmacokinetics and safety of Bβ15–42 in several species, including humans.
Animal study and phase I trial.
University hospital and contract research laboratories.
Male farm-bred Landrace pigs were subjected to 1 hr of left anterior descending coronary artery occlusion followed by 3 hrs of reperfusion. At the time of reperfusion, Bβ15–42 (2.4 mg/kg, n = 6) or random peptide (control; 2.4 mg/kg, n = 6) was administered as an intravenous bolus. As a positive control, pigs were subjected to ischemic preconditioning (n = 6). Cardiac damage and hemodynamics were recorded. Biodistribution and pharmacokinetics of Bβ15–42 were determined in rats and dogs. In a phase I trial involving 30 male healthy volunteers, pharmacokinetics and safety were tested in a randomized, double-blinded, placebo-controlled, parallel-group, single ascending dose study.
Bβ15–42 and ischemic preconditioning significantly reduced myocardial infarct size and troponin I levels. Bβ15–42 also reduces interleukin-6 levels, underlining its anti-inflammatory properties. Furthermore, in humans, the pharmacokinetics of the peptide Bβ15–42 were comparable to those of animals, and no serious adverse effects were observed.
Bβ15–42 elicits cardioprotection in pigs and is clinically safe in phase I testing of humans. This study confirms the new concept of a pathogenic role of fibrin derivatives in myocardial reperfusion injury, which can be inhibited by peptide Bβ15–42.
From the Department of Anaesthesia, University Hospital Rostock, Germany (JPR, GEFNS, TWLS); Department of General Dermatology, Division of General Dermatology, Medical University of Vienna, Austria (PP); Molecular Cardioprotection & Inflammation Group, Department of Anaesthesia, University Hospital Bristol, Bristol Royal Infirmary, United Kingdom (AK, PAZ, KZ); Molecular Cardioprotection & Inflammation Group, Department of Anaesthesia, University Hospital Dusseldorf, Germany (JM, OB, KZ); Fibrex Medical Inc., Vienna, Austria (SR, WB); Pharm-analyt Lab GmbH, Baden, Austria (DM); Department of Clinical Pharmacology, Medical University of Vienna, Austria (MW); and Department of Clinical Chemistry, University Hospital Dusseldorf, Germany (CB).
Supported, in part, by a research grant from Fibrex Medical Research & Development GmbH, Vienna, Austria.
Dr. Petzelbauer receives consultancy fees and owns shares of Fibrex Medical Inc. Dr. Reingruber owns shares of Fibrex Medical Inc. Dr. Zacharowski receives consultancy fees and owns stock options of Fibrex Medical Inc. The remaining authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail: email@example.com or firstname.lastname@example.org